Cat. No.: HY-N2118

Bilobetin

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.71%
CAS No.: 521-32-4
Formule: C₃₁H₂₀O₁₀
Masse moléculaire:552.48

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bilobetin Chemical Structure

CAS No.: 521-32-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

PPARα

PKA

Voir tous les produits spécifiques à Isoform PPAR :

Voir tous les produits spécifiques à Isoform PKA :

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform ERK :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: 12	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
HepG2	IC₅₀	>50 μM Compound: 12	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
MCF7	IC₅₀	26.5 μM Compound: 7	Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 34875389]
MGC-803	IC₅₀	>50 μM Compound: 12	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
T-24	IC₅₀	>50 μM Compound: 12	Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]

In Vitro

Bilobetin (0-40 μM, 24/48/72 h) inhibits the cell proliferation in Huh7 and HepG2 cells^[4].
Bilobetin (0-20 μM, 24 and 48 h) induces apoptosis and increases sub G1 population in Huh7 and HepG2 cells^[4].
Bilobetin (0-20 μM, 24 h) induces accumulation of ROS and DNA damage in Huh7 and HepG2 cells^[4].
Bilobetin (1-2 μM, 1 days) inhibits the phosphorylation of AKT in sebocytes^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

Huh7 and HepG2 cells
Concentration:

0, 2.5, 5, 10, 20, and 40 μM
Incubation Time:

24/48/72 h
Result:

Inhibited cell proliferation in a dose dependent manner, with IC₅₀s of 18.28 μM at 48 h in Huh7 cells, and 19 μM at 72 h in HepG2 cells.

Apoptosis Analysis^[4]

Cell Line:

Huh7 and HepG2 cells
Concentration:

0, 2.5, 5, 10, 20 μM
Incubation Time:

24/48 h
Result:

Showed the total apoptotic cell rate of 2.2, 2.2, 1.9, and 10.6% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.7, 1.5, 7.5, and 22.5% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM.
Showed the total apoptotic cell rate of 1.1, 1.2, 1.6, and 3.0% for 24 h (Huh7 cells) at 0, 5, 10, and 20 μM, and 1.5, 1.1, 3.2, and 14.2% for 48 h (Huh7 cells) at 0, 5, 10, and 20 μM, respectively.

In Vivo

Bilobetin (i.p., 12 mg/kg/day, 4 or 14 days) ameliorates hyperlipidaemia, lipotoxicity and insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet^[1].
Bilobetin (i.p., 50 mg/kg, for 7 days) induces kidney injury in rats, and promotes the trafficking of AQP-2 onto the plasma membrane in rats^[2].
Bilobetin (6 and 12 mg/kg, i.p., daily for ten days.) shows protective effects against Cisplatin (HY-17394) (7 mg/kg, i.p., a single dose on the third day)-induced testicular toxicity in rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

rats fed a high-fat diet^[1]
Dosage:

12 mg/kg/day
Administration:

i.p., 4 or 14 days after mice were fed a HFD for 8 weeks.
Result:

Increased glucose infusion rate (GIR, P < 0.05) and reduced EGP (P < 0.05) in basal and clamp states.
Reduced total TG (P < 0.01) and VLDL-TG (P < 0.01).
Enhances hepatic Intralipid-TG uptake.
Reduced the total amount of lipid level in the liver and muscle.
Promoted the phosphorylation of PPARα and the translocation of PPARα from the cytoplasm to the nucleus in rats liver.

Chemical Information

CAS No. 521-32-4
Appearance Solid
Masse moléculaire 552.48
Formule C₃₁H₂₀O₁₀
Color Light yellow to yellow
SMILES

O=C1C=C(C2=CC=C(O)C=C2)OC3=C(C4=CC(C5=CC(C6=C(O)C=C(O)C=C6O5)=O)=CC=C4OC)C(O)=CC(O)=C13
Structure Classification
- Flavonoids
- Biflavones
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Arab J Chem

2023 Jun 28, 105094.
SSRN

2025 Jan 10.

Solvant et solubilité

In Vitro:

DMSO : 125 mg/mL (226.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8100 mL

9.0501 mL

18.1002 mL

5 mM

0.3620 mL

1.8100 mL

3.6200 mL

10 mM

0.1810 mL

0.9050 mL

1.8100 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (3.76 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kou XH, et al. Bilobetin ameliorates insulin resistance by PKA-mediated phosphorylation of PPARα in rats fed a high-fat diet. Br J Pharmacol. 2012 Apr;165(8):2692-706. [Content Brief]

[2]. Wang Q, et al. Bilobetin induces kidney injury by influencing cGMP-mediated AQP-2 trafficking and podocyte cell cycle arrest. Phytomedicine. 2019 Nov;64:153073. [Content Brief]

[3]. Negm WA, et al. The Mechanistic Perspective of Bilobetin Protective Effects against Cisplatin-Induced Testicular Toxicity: Role of Nrf-2/Keap-1 Signaling, Inflammation, and Apoptosis. Biomedicines. 2022 May 13;10(5):1134 [Content Brief]

[4]. Han Ki Lee, et al. Bilobetin induces apoptosis in human hepatocellular carcinoma cells via ROS level elevation and inhibition of CYP2J2.Arabian Journal of Chemistry. Volume 16, Issue 9, September 2023, 105094.

[5]. Wang C, et al. Inhibition of Insulin-Like Growth Factor-1–Induced Sebum Production by Bilobetin in Cultured Human Sebocytes [J]. Annals of Dermatology, 2019, 31(3): 294.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8100 mL	9.0501 mL	18.1002 mL	45.2505 mL
	5 mM	0.3620 mL	1.8100 mL	3.6200 mL	9.0501 mL
	10 mM	0.1810 mL	0.9050 mL	1.8100 mL	4.5251 mL
	15 mM	0.1207 mL	0.6033 mL	1.2067 mL	3.0167 mL
	20 mM	0.0905 mL	0.4525 mL	0.9050 mL	2.2625 mL
	25 mM	0.0724 mL	0.3620 mL	0.7240 mL	1.8100 mL
	30 mM	0.0603 mL	0.3017 mL	0.6033 mL	1.5084 mL
	40 mM	0.0453 mL	0.2263 mL	0.4525 mL	1.1313 mL
	50 mM	0.0362 mL	0.1810 mL	0.3620 mL	0.9050 mL
	60 mM	0.0302 mL	0.1508 mL	0.3017 mL	0.7542 mL
	80 mM	0.0226 mL	0.1131 mL	0.2263 mL	0.5656 mL
	100 mM	0.0181 mL	0.0905 mL	0.1810 mL	0.4525 mL

Keywords

Bilobetin

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Bilobetin

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Bilobetin

Voir tous les produits spécifiques à Isoform PPAR

Voir tous les produits spécifiques à Isoform PKA

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform p38 MAPK

Voir tous les produits spécifiques à Isoform ERK

Activité biologique

Chemical Information

Publications (2)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bilobetin Related Classifications

HY-N2118 Related Classifications